Clinical Drug Investigation

, Volume 23, Issue 3, pp 193–203 | Cite as

Effects of D-003, a New Hypocholesterolaemic and Antiplatelet Compound, on Lipid Profile and Lipid Peroxidation in Healthy Volunteers

  • Gladys Castaño
  • Roberto Menéndez
  • Rosa Más
  • Nuris Ledón
  • Julio Fernández
  • Johany Pérez
  • Rosa M. González
  • Magnolia Lezcay
Original Research Article

Abstract

Background: D-003 is a mixture of long-chain aliphatic primary acids purified from sugarcane wax with hypocholesterolaemic effects proven in rabbits and healthy volunteers; it lowers serum total cholesterol (TC) and low-density lipoprotein-cholesterol (LDL-C) and increases high-density lipoprotein-cholesterol (HDL-C). D-003 also prevents lipoprotein lipid peroxidation in experimental models.

Objective: To investigate the effects of D-003 on lipid profile and lipid peroxidation in healthy human volunteers.

Participants: Forty-six healthy volunteers (24 women, 22 men).

Methods: This double-blind, randomised, placebo-controlled study investigated the effects of D-003 at 5 and 10 mg/day on the susceptibility of LDL to lipid peroxidation induced by copper ions in healthy volunteers. Forty-six individuals were randomised (1 : 2) to placebo or D-003 at 5 or 10 mg/day, the tablets being taken once a day with the evening meal for 8 weeks. Laboratory determinations and physical examination were performed at baseline and after 4 and 8 weeks of therapy, and compliance and adverse experience assessments were performed at weeks 4 and 8.

Results: All groups were well matched at baseline. At study completion, D-003 at 5 and 10 mg/day significantly (p < 0.001) lowered LDL-C, the primary response variable, by 20.8% and 28.8%, respectively. In addition, D-003 at 5 and 10 mg/day reduced (p < 0.001) TC (12.7% and 17.5%, respectively), LDL-C/ HDL-C (25.9% and 36.3%, respectively) and TC/HDL-C (18.6% and 26.3%, respectively), while significantly (p < 0.01) increasing HDL-C (7.7% and 12.4%, respectively). Triglycerides were significantly (p < 0.05) reduced (8.8% and 13.1%, respectively) with respect to baseline, but not versus placebo. Responses assessed at 4 weeks showed significant reductions of LDL-C, TC and atherogenic ratios with both doses of D-003, whereas HDL-C was significantly increased. Triglycerides, however, remained unchanged. No significant changes in any lipid profile variable occurred in the placebo group. D-003 at 5 and 10 mg/day significantly (p < 0.05) increased lag time (18.3% and 32.0%, respectively) and decreased maximum rate of diene propagation (Vmax) [12.7% and 19.1%, respectively] of copper-induced LDL peroxidation. D-003 5 and 10 mg/day attenuated the reduction of the reactivity against 2, 4, 6-trinitrobenzene sulfonic acid (TNBS) by 19.9% and 32.0%, respectively. The treatment was well tolerated. Three subjects (one from each group) discontinued the study. Only one, treated with D-003 5 mg/day, discontinued because of an adverse event (gastritis).

Conclusions: D-003 at 5 and 10 mg/day demonstrated dose-dependent cholesterol-lowering effects in healthy volunteers characterised by reductions in LDL-C, TC and atherogenic ratios, and increases in HDL-C. Effects on triglycerides were modest and uncertain. As expected from experimental studies, D-003 inhibited the susceptibility of LDL to lipid peroxidation assessed by three indicators lag time Vmax and reactivity versus TNBS. Further studies investigating the effect of larger doses and treatment duration must be conducted to confirm the reproducibility of the present results in different study populations.

Keywords

Lipid Peroxidation Lipid Profile Policosanol Paraoxonase Activity Lipid Peroxidation Assay 

Notes

Acknowledgements

This study was supported by a research grant of the West Havana Scientific Pole.

References

  1. 1.
    Falk E, Fernández-Ortiz A. Role of thrombosis in atherosclerosis and its complications. Am J Cardiol 1995; 75: 1B–7BCrossRefGoogle Scholar
  2. 2.
    Murray CJL, Lopez AD. Alternate projections of mortality and disability by cause 1990–2020. Global Burden disease Study. Lancet 1997; 349: 1498–504PubMedCrossRefGoogle Scholar
  3. 3.
    Brown MS, Goldstein JL. Heart attacks: gone with the century. Science 1996; 272: 629–30PubMedCrossRefGoogle Scholar
  4. 4.
    Frick MH, Elo O, Happa K, et al. Helsinki Heart Study: primary-prevention with gemfibrozil in middle-aged men with dyslipidemia. N Engl J Med 1987; 317: 1237–45PubMedCrossRefGoogle Scholar
  5. 5.
    Lipid Research Clinics Program. The lipid research clinics coronary primary prevention trial results: I. reduction in the incidence of coronary heart disease. JAMA 1984; 251: 351–64CrossRefGoogle Scholar
  6. 6.
    Lipid Research Clinics Program. The lipid research clinics coronary primary prevention trial results: II. the relationship of reduction in the incidence of coronary heart disease to cholesterol-lowering. JAMA 1984; 251: 365–44CrossRefGoogle Scholar
  7. 7.
    Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383–9Google Scholar
  8. 8.
    Sacks FM, Pfeffer MA., Moyé LA, et al., for the Cholesterol and Recurrent Events Trial Investigators: The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996; 335: 1001–9PubMedCrossRefGoogle Scholar
  9. 9.
    The Long-Term Intervention with Paravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and deaths with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998; 339: 1349–57CrossRefGoogle Scholar
  10. 10.
    Shepherd S, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995; 333: 1301–7PubMedCrossRefGoogle Scholar
  11. 11.
    Downs JR, Clearfield M, Weiss S, et al., for the AFCAPS/ TexCAPS Research Group. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. JAMA 1998; 279: 1615–22PubMedCrossRefGoogle Scholar
  12. 12.
    Wheeler D. Are there potential non lipid-lowering uses of statins? Drugs 1998; 56: 517–22PubMedCrossRefGoogle Scholar
  13. 13.
    Davignon J. The pleiotropic effects of drugs affecting lipid metabolism. In: Atherosclerosis. Proceedings of the Xlth International Symposium on Atherosclerosis; Elsevier 1997, 63-77Google Scholar
  14. 14.
    Palomäki A, Malminiemi K, Malminiemi O, et al. Effects of lovastatin therapy on susceptibility of LDL to oxidation during α-tocopherol supplementation. Arterioscler Thromb Vasc Biol 1999; 19: 1541–8PubMedCrossRefGoogle Scholar
  15. 15.
    Aviram M, Dankner G, Cogan U, et al. Lovastatin inhibits low-density lipoprotein oxidation and alters its fluidity and uptake by macrophages: in vitro and in vivo studies. Metabolism 1992; 41: 229–35PubMedCrossRefGoogle Scholar
  16. 16.
    Chen L, Haught WH, Yang B, et al. Preservation of endogenous antioxidant activity and inhibition of lipid peroxidation as a common mechanism of antiatherogenic effects of vitamin E, lovastatin and amlodipine. J Am Coll Cardiol 1997; 30: 569–75PubMedCrossRefGoogle Scholar
  17. 17.
    Hussein O, Schlezinger S, Rosenbest M, et al. Reduced susceptibility of low density lipoprotein (LDL) to lipid peroxidation after fluvastatin therapy no associated with the hypocholesterolemic effect of the drug and its binding to the LDL. Atherosclerosis 1997; 128: 11–8PubMedCrossRefGoogle Scholar
  18. 18.
    Leonhardt W, Kurktschen T, Meissner D, et al. Effects of pravastatin therapy on lipids, antioxidants, oxidations of low density lipoproteins and trace metals. Eur J Clin Pharmacol 1992; 53: 65–9CrossRefGoogle Scholar
  19. 19.
    González L, Marrero D, Laguna A, et al., inventors. Laboratorios Dalmer SA, assignee. Mixture of primary fatty acids of high molecular weight obtained from sugar cane wax and its pharmaceutical uses. Republic of South Africa patent 98-2744. 1998 Dec 30Google Scholar
  20. 20.
    Gámez R, Mendoza S, Mas R, et al. Dose-dependent cholesterol-lowering effects of D-003 on normocholesterolemic rabbits. Curr Ther Res Clin Exp 2000; 61: 8-16Google Scholar
  21. 21.
    Mendoza S, Gámez R, Noa M, et al. The effects of D-003 and policosanol on the lipid profile and endothelemia cells in normocholesterolemic rabbits: a head to head comparison. Curr Ther Res 2001; 62: 209–20CrossRefGoogle Scholar
  22. 22.
    Menéndez R, Más R, Amor AM, et al. Inhibition of cholesterol biosynthesis in cultured fibroblasts by D-003, a mixture of very long chain saturated fatty acids. Pharmacol Res 2001; 44: 299–304PubMedCrossRefGoogle Scholar
  23. 23.
    Castaño G, Mas R, Fernández L, et al. Assessment of the effects of D-003, a new antiplatelet and lipid-lowering compound, in healthy volunteers. Drugs R&D 2002; 3: 333–48Google Scholar
  24. 24.
    Mas R. Policosanol. Drugs of the Future 2000; 25: 569–86CrossRefGoogle Scholar
  25. 25.
    Hernández F, Illnait J, Más R, et al. Effects of policosanol on serum lipids and lipoproteins in healthy volunteers. Curr Ther Res 1992; 51: 568–75Google Scholar
  26. 26.
    Mas R, Castaño G, Illnait J, et al. Effect of policosanol in patients with type II hypercholesterolemia and additional coronary risk factors. Clin Pharmacol Ther 1998; 65: 439–47CrossRefGoogle Scholar
  27. 27.
    Castafio G, Mas R, Arruzazabala ML, et al. Effects of policosanol, pravastatin on lipid profile, platelet aggregation, endothelemia in older hypercholesterolemic patients. Int J Clin Pharm Res 1999; 19: 105–16Google Scholar
  28. 28.
    Fernández JC, Más R, Castaño G, et al. Comparison of the efficacy, safety and tolerability of policosanol versus fluvastatin in elderly hypercholesterolemic women. Clin Invest 2001; 21: 103–13CrossRefGoogle Scholar
  29. 29.
    Mirkin A, Mas R, Martinto M, et al. Efficacy and tolerability of policosanol in hypercholesterolemic postmenopausal women. Int J Clin Pharmacol Res 2001; 21: 31–42PubMedGoogle Scholar
  30. 30.
    Crespo N, Illnait J, Más R, et al. Comparative study of the efficacy and tolerability of policosanol and lovastatin in patients with hypercholesterolemia and non insulin dependent diabetes mellitus. Int J Clin Pharm Res 1999; 19(4): 117–27Google Scholar
  31. 31.
    Fraga V, Menéndez R, Amor AM, et al. Effect of policosanol on in vitro and in vivo rat liver microsomal lipid peroxidation. Arch Med Res 1997; 28: 355–60PubMedGoogle Scholar
  32. 32.
    Menéndez R, Más R, Amor AM, et al. Effects of policosanol treatment on the susceptibility of low density lipoprotein (LDL) isolated from healthy volunteers to oxidative modification in vitro. Br J Clin Pharmacol 2000; 50: 255–62PubMedCrossRefGoogle Scholar
  33. 33.
    Menéndez R, Más R, Amor AM, et al. Effects of policosanol on the susceptibility of low-density lipoprotein isolated from hypercholesterolemic patients at high coronary risk to in vitro copper-mediated lipid peroxidation: a randomized double-bind pilot study. Curr Ther Res 2000; 61: 609–20CrossRefGoogle Scholar
  34. 34.
    Menéndez R, Mas R, Pérez Y, et al. Inhibition of rat lipoprotein lipid peroxidation by the oral administration of D-003, a mixture of very long chain saturated fatty a. Can J Physiol Pharmacol 2002; 80: 13–21PubMedCrossRefGoogle Scholar
  35. 35.
    Mackness MI, Durington PN. HDL, its enzymes and its potential to influence lipid peroxidation. Atherosclerosis 1995; 115: 243–53PubMedCrossRefGoogle Scholar
  36. 36.
    Watson AD, Berliner AJ, Hama SY, et al. Protective effect of high-density lipoprotein associated paraoxonase. J Clin Invest 1995; 96: 1882–91CrossRefGoogle Scholar
  37. 37.
    Gámez R, Más R, Noa M, et al. Acute and subchronic oral toxicity of D-003 in rats. Toxicol Lett 2000; 118: 31–41PubMedCrossRefGoogle Scholar
  38. 38.
    Gámez R, González JE, Rodeiro I, et al. In vivo genotoxic evaluation of D-003, a mixture of very long-chain aliphatic acids. J Med Food 2001; 4: 85–92PubMedCrossRefGoogle Scholar
  39. 39.
    Gámez R, Rodeiro I, Fernández I, Acosta PC. A preliminary evaluation of the cytotoxic and genotoxic potential of D-003: a mixture of very long chain fatty acids. Teratog Carcinog Mutagen 2001; 21: 85–92Google Scholar
  40. 40.
    Schectman G, Hiatt J. Drug therapy for hypercholesterolemia in patients with cardiovascular disease: factors limiting achievement of lipid goals. Am J Med 1996; 100: 197–204PubMedCrossRefGoogle Scholar
  41. 41.
    Seigler L, Wu WT. Separation of serum high-density lipoprotein for cholesterol determination: ultracentrifugation vs precipitation with sodium phosphotungstat and magnesium chloride. Clin Chem 1981; 27: 838–41PubMedGoogle Scholar
  42. 42.
    Friedewald WT, Levy RI, Friederickson SD. Estimation of the concentration of low-density-lipoprotein cholesterol in plasma without of the preparative ultracentrifuge. Clin Chem 1972; 18: 499–502PubMedGoogle Scholar
  43. 43.
    Kleinveld HA, Hark-Lemmers HLM, Stalenhoef AFH, et al. Improved measurements of low-density lipoprotein susceptibility to copper-induced oxidation: application of a short procedure for isolating low-density lipoprotein. Clin Chem 1992; 38: 2066–72PubMedGoogle Scholar
  44. 44.
    Esterbauer H, Striegl H, Puhl H, et al. Continuos monitoring of in vitro oxidation of human low density lipoprotein. Free Radic Res Commun 1989; 6: 67–75PubMedCrossRefGoogle Scholar
  45. 45.
    Markwell MA, Hass SM, Bieber LL, et al. A modification of the Lowry procedure to simply protein determination in membrane and lipoprotein samples. Anal Biochem 1987; 87: 206–10CrossRefGoogle Scholar
  46. 46.
    Steinbrecher UP. Oxidation of human low-density lipoprotein results in derivatization of lysine residues of apolipoprotein B by lipid peroxides. J Biol Chem 1987; 262: 3603–8PubMedGoogle Scholar
  47. 47.
    Witztum JL, Steinberg D. Role of oxidized low-density lipoprotein in atherogenesis. J Clin Invest 1991; 88: 1785–92PubMedCrossRefGoogle Scholar
  48. 48.
    Endemann G, Stanton LW, Madden KS, et al. CD 36 is a receptor for oxidized low-density lipoprotein. J Biol Chem 1993; 268: 11811–4PubMedGoogle Scholar
  49. 49.
    Brown MS, Goldstein JL. Scavenging for receptors. Nature (London) 1990; 342: 508–9CrossRefGoogle Scholar
  50. 50.
    Ruiz J, Blanche H, James RW, et al. The role of lipid peroxidation and antioxidants in oxidative modification of LDL. Free Radic Biol Med 1992; 13: 341–6CrossRefGoogle Scholar
  51. 51.
    Keichl S, Aichner F, Gerstenbrand F. Body iron stores and presence of carotid atherosclerosis: results from the Bruneck study. Arterioscler Thromb 1994; 14: 1625–30CrossRefGoogle Scholar
  52. 52.
    Esterbauer H, Gebicki J, Puhl H, et al. The role of lipid peroxidation and antioxidant in oxidative modification of LDL. Free Radie Biol Med 1992; 13: 341–90CrossRefGoogle Scholar
  53. 53.
    Thomas CE, Jackson RL. Lipid hydroperoxides involvement in copper-dependent and independent lipid peroxidation of LDL. J Pharm Exp Ther 1991; 256: 1182–8Google Scholar
  54. 54.
    O’Leary VJ, Darley-Usmar VM, Rusell LJ, et al. Pro-oxidant effects of lipoxygenase-derived peroxides on the copper-initiated oxidation of LDL. Biochem J 1992; 282: 631–4PubMedGoogle Scholar

Copyright information

© Adis Data Information BV 2003

Authors and Affiliations

  • Gladys Castaño
    • 1
  • Roberto Menéndez
    • 2
  • Rosa Más
    • 2
  • Nuris Ledón
    • 2
  • Julio Fernández
    • 2
  • Johany Pérez
    • 2
  • Rosa M. González
    • 2
  • Magnolia Lezcay
    • 1
  1. 1.Medical Surgical Research CenterHavana CityCuba
  2. 2.Center of Natural ProductsNational Center for Scientific ResearchHavana CityCuba

Personalised recommendations